AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33628012 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilayer tablet of gemigliptin/rosuvastatin 50/20 mg
Number of subjects: 48
Study 33628012 — intervention group
Group type: COMPARATOR
Intervention: Monolayer tablet of gemigliptin/rosuvastatin 50/20 mg
Number of subjects: 48
Study 32186976 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) and dietary supplementation (vitamin D, iron, selenium)
Number of subjects: 350
Study 32186976 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM)
Number of subjects: 350
Study 36384478 — intervention group
Group type: EXPERIMENTAL
Intervention: Carer End of Life Planning Intervention (CELPI)
Number of subjects: 440
Study 34686149 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective sleeve group
Number of subjects: 60
Study 34686149 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 32383196 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine 4% with epinephrine 1:100,000
Number of subjects: 43
Study 32383196 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% with epinephrine 1:100,000
Number of subjects: 43
Study 33577389 — intervention group
Group type: COMPARATOR
Intervention: Over-minus therapy
Number of subjects: 64
Study 33577389 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-minus therapy with inward decentration of spectacle glasses
Number of subjects: 64
Study 32181503 — intervention group
Group type: EXPERIMENTAL
Intervention: NHL subclassification
Number of subjects: 516
Study 32181503 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse large B cell lymphoma
Number of subjects: 516
Study 32181503 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic lymphocytic leukaemia
Number of subjects: 516
Study 32181503 — intervention group
Group type: EXPERIMENTAL
Intervention: Burkitt lymphoma
Number of subjects: 516
Study 32181503 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage at diagnosis
Number of subjects: 516
Study 32181503 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV status
Number of subjects: 516
Study 32181503 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOG PS
Number of subjects: 516
Study 35183346 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane general anaesthesia
Number of subjects: 60
Study 35183346 — intervention group
Group type: COMPARATOR
Intervention: Resting wakefulness (Control)
Number of subjects: 60
Study 34153105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 59
Study 34153105 — intervention group
Group type: COMPARATOR
Intervention: Sleep Deprivation
Number of subjects: 59
Study 36608969 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based psychological intervention for PGD
Number of subjects: 0
Study 34444341 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical literacy-based intervention once weekly for 14 weeks
Number of subjects: 28
Study 34444341 — intervention group
Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 28
Study 32871529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained glides
Number of subjects: 88
Study 32871529 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillatory glides
Number of subjects: 88
Study 32871529 — intervention group
Group type: COMPARATOR
Intervention: Stiff shoulders
Number of subjects: 88
Study 32871529 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 88
Study 33503173 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release morphine tablets combined with celecoxib
Number of subjects: 110
Study 33503173 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release morphine tablets alone (Control)
Number of subjects: 110
Study 33582688 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Lithotripsy
Number of subjects: 90
Study 33582688 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic Lithotripsy
Number of subjects: 90
Study 36205473 — intervention group
Group type: COMPARATOR
Intervention: Connection to Health (CTH)
Number of subjects: 734
Study 36205473 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Engagement CTH (EE-CTH)
Number of subjects: 734
Study 32960327 — intervention group
Group type: EXPERIMENTAL
Intervention: High-power Thulium Fibre Laser (TFL) with suction
Number of subjects: 54
Study 32100681 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorinated drinking water and safe storage (W)
Number of subjects: 0
Study 32100681 — intervention group
Group type: EXPERIMENTAL
Intervention: Upgraded sanitation (S)
Number of subjects: 0
Study 32100681 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing promotion (H)
Number of subjects: 0
Study 32100681 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined water, sanitation, and handwashing (WSH)
Number of subjects: 0
Study 32100681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention including lipid‐based nutrient supplements
Number of subjects: 0
Study 32100681 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined WSH plus nutrition (WSHN)
Number of subjects: 0
Study 32100681 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 0
Study 33777422 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised physical activity consultations, pedometers, monthly messages via web-based application
Number of subjects: 232
Study 35715966 — intervention group
Group type: EXPERIMENTAL
Intervention: School of Hard Talks intervention (8 hours of training in communication skills using motivational interviewing techniques)
Number of subjects: 62
Study 34563169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg daily, orally)
Number of subjects: 0
Study 32193169 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclaimer comments that critiqued the images as unrealistic
Number of subjects: 181
Study 32193169 — intervention group
Group type: COMPARATOR
Intervention: Traditional comments that idealized the images
Number of subjects: 181
Study 32193169 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclaimer comments
Number of subjects: 181
Study 32193169 — intervention group
Group type: COMPARATOR
Intervention: Idealized Comment condition
Number of subjects: 181
Study 32193169 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 181
Study 35329066 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise group (AerG)
Number of subjects: 102
Study 35329066 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval group (IntG)
Number of subjects: 102
Study 35329066 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (ComG)
Number of subjects: 102
Study 35329066 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 102
Study 32005255 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased availability of lower energy options (75% of menu options lower energy)
Number of subjects: 1743
Study 32005255 — intervention group
Group type: COMPARATOR
Intervention: Menu energy labelling present
Number of subjects: 1743
Study 32005255 — intervention group
Group type: COMPARATOR
Intervention: Menu energy labelling absent
Number of subjects: 1743
Study 32005255 — intervention group
Group type: COMPARATOR
Intervention: Baseline availability of lower energy options (25% of menu options lower energy)
Number of subjects: 1743
Study 33760976 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (156 subjects)
Number of subjects: 180
Study 33760976 — intervention group
Group type: COMPARATOR
Intervention: Test group (24 subjects)
Number of subjects: 180
Study 33374947 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg/bm of caffeine (3COF)
Number of subjects: 17
Study 33374947 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg/bm of caffeine (6COF)
Number of subjects: 17
Study 33374947 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee (PLA)
Number of subjects: 17
Study 36174134 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference-focused psychotherapy (TFP)
Number of subjects: 194
Study 36174134 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive psychodynamic therapy (SPT)
Number of subjects: 194
Study 36174134 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy (DBT)
Number of subjects: 194
Study 36174134 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced treatment as usual (eTAU)
Number of subjects: 194
Study 32979042 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Patient Navigation program (PN+)
Number of subjects: 120
Study 32979042 — intervention group
Group type: COMPARATOR
Intervention: Control (PN)
Number of subjects: 120
Study 35941895 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE)
Number of subjects: 160
Study 35941895 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling group (n = 120)
Number of subjects: 160
Study 35941895 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model
Number of subjects: 160
Study 35941895 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling group
Number of subjects: 160
Study 35941895 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation group
Number of subjects: 160
Study 33895220 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal PEEP (8.8 ± 2.4 cmH2O) with decremental titration after ARM
Number of subjects: 58
Study 33895220 — intervention group
Group type: COMPARATOR
Intervention: Standard 5 cmH2O PEEP until the end of OLV
Number of subjects: 58
Study 32515156 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 9
Study 33601948 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) with 120 ml ropivacaine 0.2% plus epinephrine 0.5 µ/ml
Number of subjects: 63
Study 33601948 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 63
Study 33601948 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 63
Study 33383447 — intervention group
Group type: EXPERIMENTAL
Intervention: SSS07 (5, 15, 30, 50, 75, and 100 mg)
Number of subjects: 71
Study 33383447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 33383447 — intervention group
Group type: EXPERIMENTAL
Intervention: SSS07 (lower doses)
Number of subjects: 71
Study 33383447 — intervention group
Group type: EXPERIMENTAL
Intervention: SSS07 (100 mg)
Number of subjects: 71
Study 32901235 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (15 mg/kg)
Number of subjects: 102
Study 32901235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 32901235 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 102
Study 34049916 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Mile schools (intervention group)
Number of subjects: 3533
Study 34049916 — intervention group
Group type: COMPARATOR
Intervention: Non-Daily Mile schools (control group)
Number of subjects: 3533
Study 32068436 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR341402 (SAR‐Asp)
Number of subjects: 597
Study 32068436 — intervention group
Group type: COMPARATOR
Intervention: NN‐Asp (originator insulin aspart)
Number of subjects: 597
Study 35778368 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity shockwave therapy (LiSWT)
Number of subjects: 51
Study 35778368 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 51
Study 34446156 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg once daily
Number of subjects: 5522
Study 35118992 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral plate tubularization
Number of subjects: 43
Study 35118992 — intervention group
Group type: COMPARATOR
Intervention: Mathieu technique
Number of subjects: 43
Study 32061505 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric broad-spectrum antibiotic therapy
Number of subjects: 0
Study 32061505 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial oral or parenteral therapy
Number of subjects: 0
Study 32061505 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter courses of therapy
Number of subjects: 0
Study 32061505 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic time out protocol
Number of subjects: 0
Study 34986194 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention of minimal and unprocessed foods for three to six months, including five times per week green vegetables, three times per week beef, daily 200-300 mL whole cow's milk (3.4% fat), and whole dairy butter (80% fat) on each slice of bread.
Number of subjects: 267
Study 34986194 — intervention group
Group type: COMPARATOR
Intervention: Control group continued their usual dietary habits.
Number of subjects: 267
Study 34986194 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention of minimal and unprocessed foods for three to six months.
Number of subjects: 267
Study 33323442 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3 g/day of n-3 polyunsaturated fatty acids)
Number of subjects: 128
Study 33323442 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 128
Study 34339988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure (200 ppb)
Number of subjects: 22
Study 34339988 — intervention group
Group type: COMPARATOR
Intervention: Clean air exposure
Number of subjects: 22
Study 33615404 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic double-bundle ACL reconstruction (DB)
Number of subjects: 57
Study 33615404 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic single-bundle ACL reconstruction (SB)
Number of subjects: 57
Study 32444670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical dilatation at the 3rd, 5th, and 8th week after LEEP (Intervention Group A)
Number of subjects: 404
Study 32444670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical dilatation at the 4th, 8th, and 12th week after LEEP (Intervention Group B)
Number of subjects: 404
Study 32444670 — intervention group
Group type: COMPARATOR
Intervention: Control group (without any intervention)
Number of subjects: 404
Study 34560806 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose alteplase regimen
Number of subjects: 650
Study 34560806 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin anticoagulation
Number of subjects: 650
Study 33538113 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg subcutaneously every 8 weeks
Number of subjects: 3021
Study 33538113 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg subcutaneously every 8 weeks
Number of subjects: 3021
Study 33538113 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs (oral naproxen, celecoxib, or diclofenac twice daily)
Number of subjects: 3021
Study 33636453 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 396
Study 33636453 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 396
Study 32202075 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 1377
Study 32202075 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 1377
Study 32202075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1377
Study 35836281 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Drop Height Drop Jump Training (OG)
Number of subjects: 55
Study 35836281 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Drop Height Drop Jump Training (HG)
Number of subjects: 55
Study 35836281 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Training (WG)
Number of subjects: 55
Study 35836281 — intervention group
Group type: COMPARATOR
Intervention: Lower Drop Height Drop Jump Training (LG)
Number of subjects: 55
Study 35836281 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 55
Study 33454216 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum procalcitonin (PCT)
Number of subjects: 25
Study 33454216 — intervention group
Group type: EXPERIMENTAL
Intervention: LRINEC score
Number of subjects: 25
Study 33454216 — intervention group
Group type: COMPARATOR
Intervention: Control group (cellulitis)
Number of subjects: 25
Study 35879728 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐CBT (five sessions)
Number of subjects: 138
Study 35879728 — intervention group
Group type: COMPARATOR
Intervention: EDU (online education about surgery and healthy lifestyle)
Number of subjects: 138
Study 35879728 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 138
Study 34684536 — intervention group
Group type: EXPERIMENTAL
Intervention: Privative diet (avoiding meat, gluten, and lactose)
Number of subjects: 40
Study 34684536 — intervention group
Group type: COMPARATOR
Intervention: Control balanced diet (including meat, gluten, and lactose)
Number of subjects: 40
Study 32844712 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (TTh) for 2 years
Number of subjects: 55
Study 32844712 — intervention group
Group type: COMPARATOR
Intervention: Placebo during the first year, followed by Testosterone therapy (TTh) during the second year
Number of subjects: 55
Study 36151609 — intervention group
Group type: EXPERIMENTAL
Intervention: Health‐Smart Weight Loss (HSWL) Program
Number of subjects: 683
Study 36151609 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient‐Centred Culturally Sensitive Weight Loss Maintenance Program (PCCS‐WLM Program)
Number of subjects: 683
Study 36151609 — intervention group
Group type: COMPARATOR
Intervention: Standard Behavioural Weight Loss Maintenance Program (SB‐WLM Program)
Number of subjects: 683
Study 33691278 — intervention group
Group type: EXPERIMENTAL
Intervention: Banister TRIMP
Number of subjects: 9
Study 33691278 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucia TRIMP
Number of subjects: 9
Study 33691278 — intervention group
Group type: EXPERIMENTAL
Intervention: Edwards TRIMP
Number of subjects: 9
Study 33691278 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Stress Score
Number of subjects: 9
Study 33691278 — intervention group
Group type: EXPERIMENTAL
Intervention: Session Rating of Perceived Exertion
Number of subjects: 9
Study 33691278 — intervention group
Group type: EXPERIMENTAL
Intervention: Kilojoules
Number of subjects: 9
Study 33876339 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser‐assisted flapless corticotomy
Number of subjects: 18
Study 33876339 — intervention group
Group type: COMPARATOR
Intervention: Control side (conventional technique)
Number of subjects: 18
Study 34941558 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Anchor (FA)
Number of subjects: 101
Study 34941558 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 101
Study 34941558 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to Anchoring Strategy
Number of subjects: 101
Study 34263641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms for overall survival (OS)
Number of subjects: 6947
Study 34263641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms for cancer-specific survival (CSS)
Number of subjects: 6947
Study 34263641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms for OS and CSS
Number of subjects: 6947
Study 33306589 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training to failure
Number of subjects: 12
Study 33306589 — intervention group
Group type: COMPARATOR
Intervention: Resistance training not to failure
Number of subjects: 12
Study 32134048 — intervention group
Group type: EXPERIMENTAL
Intervention: Template group (3D printed guide template)
Number of subjects: 34
Study 32134048 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (traditional surgical methods)
Number of subjects: 34
Study 35418412 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-and-treat plus L. reuteri
Number of subjects: 272
Study 35418412 — intervention group
Group type: COMPARATOR
Intervention: Test-and-treat plus placebo
Number of subjects: 272
Study 35418412 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus L. reuteri
Number of subjects: 272
Study 35418412 — intervention group
Group type: COMPARATOR
Intervention: Standard care plus placebo
Number of subjects: 272
Study 33554885 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) for 15 sessions
Number of subjects: 60
Study 33554885 — intervention group
Group type: EXPERIMENTAL
Intervention: Low power laser therapy (LPLT) for 15 sessions
Number of subjects: 60
Study 33554885 — intervention group
Group type: COMPARATOR
Intervention: Control group (KT)
Number of subjects: 60
Study 33554885 — intervention group
Group type: COMPARATOR
Intervention: Control group (LPLT)
Number of subjects: 60
Study 32114185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (CBTI)
Number of subjects: 165
Study 32114185 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene (SH) attention control condition
Number of subjects: 165
Study 34542830 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab (120 mg/month with 240 mg loading dose)
Number of subjects: 432
Study 34542830 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab (120 mg/month)
Number of subjects: 432
Study 34542830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432
Study 33109271 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Post‐Admission Cognitive Therapy for Suicidality (GPACTS)
Number of subjects: 240
Study 33109271 — intervention group
Group type: COMPARATOR
Intervention: Individual Supportive Therapy (IST)
Number of subjects: 240
Study 32129815 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted pancreaticoduodenectomy (RPD)
Number of subjects: 187
Study 34523807 — intervention group
Group type: COMPARATOR
Intervention: Itepekimab (0.3, 1, 3, or 10 mg/kg infusion or 150 mg subcutaneously)
Number of subjects: 63
Study 34523807 — intervention group
Group type: COMPARATOR
Intervention: Itepekimab (75 or 150 mg weekly for 4 weeks subcutaneously)
Number of subjects: 63
Study 34523807 — intervention group
Group type: COMPARATOR
Intervention: Itepekimab
Number of subjects: 63
Study 32348539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection every 4 weeks (2q4)
Number of subjects: 107
Study 32348539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection every 8 weeks (2q8)
Number of subjects: 107
Study 32348539 — intervention group
Group type: COMPARATOR
Intervention: Macular laser photocoagulation (laser control)
Number of subjects: 107